📰 Librexia Stroke News
Librexia Stroke News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Librexia Stroke. Real-time updates on events, politics, business and more.
May 21, 2024
The results showed that individuals treated with milvexian had a prolonged aPTT in a dose-dependent manner with limited effects of PT.
May 25, 2023
Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA. The designation covers all three phase 3 Librexia development studies of the investigational oral factor XIa inhibitor: Librexia Stroke, Librexia ACS and Librexia AF. According to a company press release, the